GUSPERIMUS manufacturers and suppliers

GUSPERIMUS suppliers

GUSPERIMUS

CAS:: 104317-84-2

MF:: C17H37N7O3

MW:: 387.52

Suppliers by country/region

Company Type

Trader

Properties

Safety Information

Use

Gusperimus, a synthetic derivative of the antitumor antibiotic spergualin originally isolated from Bacillus laterosporus, was introduced in Japan as a treatment for accelerated and acute rejection reactions after kidney transplants. It possesses strong immunosuppressive activity including suppression of autoimmune disease, prolongation of survival of transplant allografts, induction of transplant tolerance, reversal of allograft rejection, inhibition of antibody responses, and suppression of delayed-type hypersensitivity. Although its activity is comparable to other agents as monotherapy, gusperimus in combination therapy (such as with cyclosporine A) has been reported to exhibit exceptional activity for prevention of transplant rejection and to induce long term tolerance. The mechanism of action appears to be due to inhibition of differentiation and proliferation of effector cells, including cytotoxic T cells and antibody producing B cells. Gusperimus is also in clinical trials for the treatment of graft rejection, multiple sclerosis, systemic lupus, diabetes mellitus, rheumatoid arthritis, nephrosis, and as an anticancer agent.

You can find GUSPERIMUS suppliers, manufacturers, and distributors from countries such as United States, United Kingdom and the CHINA here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.